Skip to main content

Table 3 Resistance comparing IM versus VLM patients

From: Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda

 

IM

VLM

 

(N = 70)

(N = 39)

NRTI mutations

  

 Any TAMs

34 (49)

2 (5)

 1 TAMs

13 (19)

1 (3)

 2 TAMs

14 (20)

1 (3)

 3+ TAMs

7 (10)

0 (0)

41L

8 (11)

0 (0)

65R

1 (1)

3 (8)

67 N

11 (16)

1 (3)

70R

13 (19)

1 (3)

184I/V

61 (87)

19 (49)

210W

1 (1)

0 (0)

215F/Y

25 (36)

1 (3)

NNRTI mutations

  

 Any NNRTI mutation

63 (90)

23 (59)

 90I

5 (7)

0 (0)

 98 G

5 (7)

0 (0)

101E

8 (11)

1 (3)

103N

23 (33)

10 (26)

 108I

10 (14)

2 (5)

 138A/G

3 (4)

0 (0)

 179D

1 (1)

0 (0)

181C/I

22 (31)

6 (15)

188L/H

3 (4)

1 (3)

190A/S

13 (19)

6 (15)

225H

6 (9)

0 (0)

230L

1 (1)

0 (0)

  1. Bold: major mutations.IM: Immunologically monitored; VLM: Virologically monitored; NRTI: nucleoside reverse transcriptase inhibitor; TAMS: thymidine analogue mutations; NNRTI: non-nucleoside reverse transcriptase inhibitor.